Specialties

The current state of digital pathology, molecular diagnostics and biobanking in renal cancer: Kidney Cancer Association Consensus Statement

Conference

IKCS-EU 2024

Author(s)

Blackmur et al.

Type

Proceedings article

17 October 2024 15:36

Influence of immunotherapy combinations on outcomes in sarcomatoid metastatic renal cell carcinoma: results from the UK Renal Oncology Collaborative

Conference

IKCS-EU 2024

Author(s)

Roy et al.

Type

Proceedings article

17 October 2024 15:35

Real-world experience of adjuvant pembrolizumab in resected renal cancer

Conference

IKCS-EU 2024

Author(s)

James et al.

Type

Proceedings article

17 October 2024 15:30

Evaluation of bone response in metastatic renal cell carcinoma treated in first-line with immunotherapy-based combinations

Conference

IKCS-EU 2024

Author(s)

Moinard-Butot et al.

Type

Proceedings article

17 October 2024 15:26

Fumarate hydratase-deficient renal cell carcinoma

Conference

IKCS-EU 2024

Author(s)

Ürün

Type

Proceedings article

17 October 2024 15:25

Treatment of residual RCC following first-line systemic therapy

Conference

IKCS-EU 2024

Author(s)

Ürün

Type

Proceedings article

17 October 2024 15:22

OS benefit in ARMANI, but is it worth it?

Presented By

Dr Giovanni Randon, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

Trial

Phase 3, ARMANI

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 12:08

SPOTLIGHT on new targets in immunotherapy: claudin 18.2

Presented By

Prof. Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, SPOTLIGHT

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 12:03

AI facilitates early detection of hepatocellular carcinoma

Presented By

Dr Kin Nam Kwok, Hong Kong University, Hong Kong

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:59

Encouraging efficacy of anti-claudin 18.2 ADC in G/GEJ cancer

Presented By

Dr Jia Liu, St Vincent’s Hospital Sydney, Australia

Trial

Phase 1

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:58

Durvalumab plus chemotherapy enhances 3-year survival in advanced biliary tract cancer

Presented By

Prof. Do-Youn Oh, Seoul National University, Korea

Trial

Phase 3, TOPAZ-1

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:53

New analyses validate TAP and CPS scores for PD-L1 expression

Presented By

Prof. Markus Moehler; Prof. Eric Raymond

Trial

Phase 3, RATIONALE-305; RATIONALE-306

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:39

KEYNOTE-585: negative trial, but long-term benefit in PD-L1-high/MSI subgroups?

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, KEYNOTE-585

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:30

MINOTAUR: Promising phase 1 data for lunresertib plus FOLFIRI

Presented By

Dr Elisa Fontana, Sarah Cannon Research Institute, UK

Trial

Phase 1, MINOTAUR

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:09

No survival benefit of tumour debulking for patients with multi-organ metastatic CRC

Presented By

Dr Elske Gootjes, Radboudumc, the Netherlands

Trial

Phase 3, ORCHESTRA

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:53

Benefit of first-line nivolumab/ipilimumab in MSI-H/dMMR metastatic CRC

Presented By

Prof. Heinz-Josef Lenz, University of Southern California Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 3, CheckMate 8HW

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:44

Neoadjuvant checkpoint blockade in MSI-H/dMMR CRC

Trial

Phase 1/2, NICHE-2, NEOPRISM-CRC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:36

CodeBreaK 300: Promising survival trends in KRAS G12C-mutated mCRC

Presented By

Prof. Marwan Fakih, City of Hope Comprehensive Cancer Center, CA, USA

Trial

Phase 3, CodeBreaK 300

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:26

FLOT outperforms CROSS in resectable oesophageal cancer

Presented By

Prof. Jens Höppner, University of Bielefeld, Germany

Trial

Phase 3, ESOPEC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:14

Nivolumab/ipilimumab combination outperforms TKIs in unresectable HCC

Presented By

Dr Peter Galle, Universitätsmedizin Mainz, Germany

Trial

Phase 3, CheckMate 9DW

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:10

No advantage of neoadjuvant radiochemotherapy over neoadjuvant chemotherapy in borderline resectable pancreatic cancer

Presented By

Dr Masafumi Ikeda, National Cancer Center Hospital East, Japan

Trial

Phase 3, GABARNANCE

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:06

Determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies

18 March 2024 09:53

Recommendation to screen for colorectal cancer by full colonoscopy in first-degree relatives of patients

18 March 2024 09:42

Interview: The winding road to curing metastatic colorectal cancer

Expert

Dr Eduard Batlle, Institute for Research in Biomedicine Barcelona, Spain

23 February 2024 15:22

Adding docetaxel to standard-of-care does not improve outcomes in gastric cancer

Presented By

Dr Anant Ramaswamy, Tata Memorial Centre, India

Trial

Phase 3, DOC-GC

Conference

ASCO GI 2024

Type

News article

13 February 2024 14:37

Thoracoscopic oesophagectomy non-inferior to open surgery in thoracic oesophageal cancer

Presented By

Prof. Hiroya Takeuchi, Hamamatsu University, Japan

Trial

Phase 3, JCOG1409

Conference

ASCO GI 2024

Type

News article

13 February 2024 14:33

KEYNOTE-590: 5-Year outcomes confirm benefit of pembrolizumab in oesophageal cancer

Presented By

Prof. Manish Shah, Weill Cornell Medicine, NY, USA

Trial

Phase 3, KEYNOTE-590

Conference

ASCO GI 2024

Type

News article

13 February 2024 14:26

New standard-of-care for locally advanced oesophageal squamous cell carcinoma?

Presented By

Prof. Yin Li, National Cancer Center, China

Trial

Phase 3, ESCORT-NEO

Conference

ASCO GI 2024

Type

News article

13 February 2024 14:23

MATTERHORN: FLOT plus durvalumab leads to high pCR rate in gastric cancer

Presented By

Dr Yelena Janjigian, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, MATTERHORN

Conference

ASCO GI 2024

Type

News article

13 February 2024 14:19

SKYSCRAPER-08: Adding tiragolumab to oesophageal cancer regimen improves outcomes

Presented By

Prof. Chih-Hung Hsu, National Taiwan University Hospital, Taiwan

Trial

Phase 3, SKYSCRAPER-08

Conference

ASCO GI 2024

Type

News article

13 February 2024 14:17

CheckMate 648: More quality time for patients with oesophageal cancer on nivolumab

Presented By

Prof. Ian Chau, Royal Marsden Hospital, UK

Trial

Phase 3, CheckMate 648

Conference

ASCO GI 2024

Type

News article

13 February 2024 14:13

Promising efficacy data for next-gen FGFR inhibitor tinengotinib in CCA

Presented By

Dr Milind Javle, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

ASCO GI 2024

Type

News article

13 February 2024 13:05

NETTER-2: Practice-changing results for 177Lu-DOTATATE in GEP-NETs

Presented By

Dr Simron Singh, University of Toronto, Canada

Trial

Phase 3, NETTER-2

Conference

ASCO GI 2024

Type

News article

13 February 2024 13:03

EMERALD-1: TACE plus immunotherapy meets primary endpoint in unresectable HCC

Presented By

Dr Riccardo Lencioni, University of Pisa, Italy

Trial

Phase 3, EMERALD-1

Conference

ASCO GI 2024

Type

News article

13 February 2024 12:57

Can adjuvant radiotherapy improve outcomes in resected HCC with narrow margin?

Presented By

Prof. Ming Kuang, Sun Yat-sen University, China

Trial

Phase 2, RAISE

Conference

ASCO GI 2024

Type

News article

13 February 2024 12:53

Encouraging preliminary data for glecirasib in pancreatic ductal adenocarcinoma

Presented By

Dr Jian Li, Peking University Cancer Hospital and Institute, China

Trial

Phase 1/2, JAB-21822-1001, JAB-21822-1002

Conference

ASCO GI 2024

Type

News article

13 February 2024 12:51

ALPACA: Promising results for dose de-escalated regimen of gemcitabine/nab-paclitaxel in metastatic PDAC

Presented By

Prof. Frank Kullmann, Hospital Weiden, Germany

Trial

Phase 2, ALPACA (AIO-PAK-0114)

Conference

ASCO GI 2024

Type

News article

13 February 2024 12:48

CheckMate 8HW: Excellent results for nivolumab plus ipilimumab in MSI-H/dMMR mCRC

Presented By

Prof. Thierry André, Sorbonne University, France

Trial

Phase 3, CheckMate 8HW

Conference

ASCO GI 2024

Type

News article

13 February 2024 12:44

Can ctDNA-directed therapy improve outcomes in low-risk colon cancer?

Presented By

Dr Van Morris, MD Anderson Cancer Center, TX, USA

Trial

Phase 2, NRG-GI005 (COBRA)

Conference

ASCO GI 2024

Type

News article

13 February 2024 12:40

Clinical biomarkers may guide therapy selection in RAS wildtype mCRC

Presented By

Dr Julian Holch, Ludwig-Maximilians-University of Munich, Germany

Trial

Phase 3, FIRE-3 (AIO KRK0306)

Conference

ASCO GI 2024

Type

News article

13 February 2024 12:31

Laparoscopic or open surgery in low rectal cancer?

Presented By

Prof. Pan Chi, Fujian Medical University, China

Trial

LASRE

Conference

ASCO GI 2024

Type

News article

13 February 2024 12:27

Investigational agent DKN-01 promising for advanced MSS CRC

Presented By

Dr Meredith Pelster, Sarah Cannon Research Institute, TN, USA

Trial

Phase 2, DeFianCe

Conference

ASCO GI 2024

Type

News article

13 February 2024 12:10

Two potential new first-line standards of care in metastatic urothelial cancer

Presented By

Prof. Thomas Powles, Queen Mary University of London, UK

Trial

Phase 3, EV-302/KEYNOTE-A39; CheckMate 901

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 12:19

Perioperative durvalumab/FLOT improves pCR in gastric cancer

Presented By

Prof. Salah-Eddin Al-Batran, Northwest Hospital Frankfurt, Germany

Trial

Phase 3, MATTERHORN

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 10:58

Active surveillance after neoadjuvant chemoradiotherapy in oesophageal cancer

Presented By

Dr Berend van der Wilk, Erasmus Medical Centre, the Netherlands

Trial

Phase 3, SANO

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 10:48

FOLFIRINOX equals gemcitabine-based chemoradiotherapy in neoadjuvant setting for pancreatic cancer

Presented By

Prof. Bas Groot Koerkamp, Erasmus Medical Centre, the Netherlands

Trial

Phase 3, PREOPANC-2

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 10:35

Modified FLOT regime outperforms FOLFOX in advanced/metastatic gastric/gastroesophageal junction adenocarcinoma

Presented By

Prof. Aziz Zaanan, Université Paris Cité, France

Trial

Phase 3, GASTROFOX

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 10:30

How to deal with at-risk patients above the CRC screening age limit?

Presented By

Dr Esther Toes-Zoutendijk, Erasmus University Medical Center, the Netherlands

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:05

European CRC screening needs to be revised

Presented By

Dr Julian Prosenz, Karl Landsteiner University of Health Sciences, Austria

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:02

Epinephrine boosts efficiency in gastric ESD

Presented By

Dr Hon Chi Yip, The Chinese University of Hong Kong, China

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 14:38

7-year outcomes of PRODIGE 23 trial

Presented By

Prof. Thierry Conroy, Institut de Cancérologie de Lorraine, France

Trial

Phase 3, PRODIGE 23

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 10:04

Neoadjuvant chemotherapy may be viable option in locally advanced colon cancer

Presented By

Dr Lars Hendrik Jensen, University of Southern Denmark, Denmark

Trial

Phase 3, NeoCol

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 10:00

De-escalation of neoadjuvant treatment of locally advanced rectal cancer is non-inferior

Presented By

Dr Deborah Schrag, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, PROSPECT

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:58

No improved OS in pancreatic cancer after neoadjuvant mFOLFIRINOX

Presented By

Prof. Knut Labori, Oslo University Hospital, Norway

Trial

Phase 2, NorPACT-1

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:35

AI detects gastric cancer with high accuracy in common blood tests

Presented By

Mr Tsz Chun Bryan Wong, Hong Kong University of Science and Technology, Hong Kong

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:34

Colorectal cancer: Aspirin and NSAIDs could reduce the risk of early-onset adenomas

Presented By

Dr Cassandra Fritz, Washington University School of Medicine, MO, USA

Conference

DDW 2023

Type

News article

13 June 2023 13:38

PIPAC technique shows promise for unresectable colorectal peritoneal metastases

Presented By

Dr Vincent van de Vlasakker, Catharina Hospital, the Netherlands

Trial

Phase 2, CRC-PIPAC-II

Conference

DDW 2023

Type

News article

13 June 2023 13:36

First-line NALIRIFOX superior to standard treatment in mPDAC

Presented By

Prof. Zev Wainberg, University of California Los Angeles, CA, USA

Trial

Phase 3, NAPOLI-3

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:37

Novel approach delivers quality-of-life benefits for patients with pancreatic cancer

Presented By

Dr Yaacov Lawrence, Sheba Medical Center, Israel

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:34

Palliative radiation therapy improves hepatic pain in HCC and liver metastasis

Presented By

Prof. Laura Dawson, Princess Margaret Cancer Centre, Canada

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:30

Improved survival following postoperative sorafenib plus TACE in HCC

Presented By

Prof. Ming Kuang, The First Affiliated Hospital, China

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:28

Quality-of-life benefits for tislelizumab in uHCC

Presented By

Prof. Richard Finn, University of California Los Angeles, CA, USA

Trial

Phase 3, RATIONALE-301

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:26

Stereotactic body radiation therapy beneficial for patients with locally advanced HCC

Presented By

Prof. Laura Dawson, Princess Margaret Cancer Centre, Canada

Trial

Phase 3, NRG/RTOG1112

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:23

SWOG 1815, first-ever phase 3 trial in BTC, fails

Presented By

Prof. Rachna Shroff, University of Arizona Cancer Center, AZ, USA

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:20

IMbrave 151 missed primary endpoint in advanced BTC

Presented By

Prof. Anthony El-Khoueiry, USC Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 2, IMbrave151

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:15

Acceptable safety profile and encouraging efficacy of nanvuranlat in BTC

Presented By

Dr Junji Furuse, Kanagawa Cancer Center, Japan

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:11

Combination botensilimab plus balstilimab demonstrates promising activity in heavily pre-treated MSS CRC

Presented By

Prof. Anthony El-Khoueiry, Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 1, C-800

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:06

Mutation-based selection to identify patients suitable for panitumumab treatment

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, PARADIGM

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:01

Fucoidan associated with quality-of-life benefits in patients with rectal cancer receiving CCRT

Presented By

Prof. Jaw-Yuan Wang, Pingtung Hospital, Taiwan

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:58

ctDNA appears useful in monitoring patients with anal cancer undergoing CRT

Presented By

Dr Janet Alvarez, Memorial Sloan Kettering Cancer Center, NY, USA

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:55

SUNLIGHT trial meets primary endpoint in refractory metastatic CRC

Presented By

Prof. Josep Tabernero, Val d’Hebron University Hospital and Institute of Oncology, Spain

Trial

Phase 3, SUNLIGHT

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:45

Does cell-free DNA influence MRD testing in post-operative colon cancer?

Presented By

Dr Stacey Cohen, University of Washington, WA, USA

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:41

OPERA: surgery may be avoided with adequate therapy in rectal cancer

Presented By

Prof. Arthur Sun Myint, Clatterbridge Cancer Centre, UK

Trial

Phase 3, OPERA

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:39

Can we improve total neoadjuvant therapy for rectal cancer?

Presented By

Dr Thomas George, University of Florida, FL, USA

Trial

Phase 2, NRG-GI002

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:36

Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, SPOTLIGHT

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:31

Regorafenib offers survival benefit for patients with pre-treated gastric cancer

Presented By

Prof. Nick Pavlakis, University of Sydney, Australia

Trial

Phase 3, INTEGRATE IIa

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:24

Radiotherapy or not in locally advanced oesophageal or junctional cancer?

Presented By

Prof. Maeve Lowery, St James’s Hospital, Ireland

Trial

Phase 3, Neo-AEGIS

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:20

Neoadjuvant immunotherapy is safe and efficacious in a phase 2 gastric cancer trial

Presented By

Dr Filippo Pietrantonio, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

Trial

Phase 2, INFINITY

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:19

S-1 adjuvant chemotherapy: 4 or 8 courses in stage 2 gastric cancer?

Presented By

Dr Souya Nunobe, Cancer Institute Hospital, Japan

Trial

Phase 3, OPAS-1

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:18

LATG/LAPG demonstrates excellent long-term efficacy in stage 1 gastric cancer

Presented By

Dr Shinichi Sakuramoto, Saitama Medical University International Medical Center, Japan

Trial

JCOG1401

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:15

3-year follow-up data confirms benefits of nivolumab plus chemotherapy

Presented By

Dr Yelena Janjigian, Memorial Sloan Kettering Cancer, NY, USA

Trial

Phase 3, CheckMate 649

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:10

Long-term results for nivolumab plus chemotherapy and nivolumab plus ipilimumab in oesophageal cancer

Presented By

Dr Ken Kato, National Cancer Center Hospital, Japan

Trial

Phase 3, CheckMate 648

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:02

Promising phase 2 results for HER-Vaxx in gastric cancer

Presented By

Dr Tanuj Chawla, Tata Medical Center, India

Trial

Phase 2, HERIZON

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:00

ASCO GI 2023 Highlights Podcast

Presented By

Robert van den Heuvel, Medicom

Conference

ASCO GI 2023

6 February 2023 23:36

Novel regimen may avoid TME surgery in rectal cancer

Expert

Dr Myriam Chalabi, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands

Trial

Phase 1/2, TARZAN

Conference

ASCO GI 2023

3 February 2023 10:43

Palliative radiation therapy improved hepatic pain in HCC and liver metastasis

Expert

Dr Laura Dawson, Princess Margaret Cancer Centre, Canada

Conference

ASCO GI 2023

3 February 2023 10:37

Immunotherapy response may be modulated by microbiome

Presented By

Dr Johannes Björk, University Medical Center Groningen, the Netherlands

Trial

PRIMM

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:48

Computer-aided colonoscopies improved adenoma detection rates

Presented By

Dr Michiel Maas, Raboud UMC, the Netherlands

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:44

Benefit of colon cancer screening with colonoscopy lower than anticipated

Presented By

Prof. Michael Bretthauer, Oslo University, Norway

Trial

Phase 3, NordICC

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:41

Screening-detected colorectal cancers may have superior surgical outcomes

Presented By

Dr Jannie Dressler, Bispebjerg Hospital, Denmark

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:37

Detection of Europe´s deadliest cancer: much room for improvement

Presented By

Dr Nosheen Umar, University of Birmingham, UK

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:21

Addition of pembrolizumab to lenvatinib does not improve OS in advanced HCC

Presented By

Prof. Richard Finn, David Geffen School of Medicine, CA, USA

Trial

Phase 3, LEAP-002

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:37

New, highly selective inhibitor of FGFR2 driver alterations and resistance mutations

Presented By

Prof. Antoine Hollebecque, Institut Gustave Roussy, France

Trial

Phase 1/2, REFOCUS

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:35

Chemo-immunotherapy in gastric cancer is more effective when administered in parallel

Presented By

Prof.  Sylvie Lorenzen, Klinikum rechts der Isar, TU München, Germany

Trial

Phase 2, Moonlight

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:31

High pathological responses to neoadjuvant immune checkpoint inhibition in locally advanced dMMR colon cancer

Presented By

Dr Miriam Chalabi, Netherlands Cancer Institute, the Netherlands

Trial

NICHE-2

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:28

Fruquintinib: a potential new treatment for patients with refractory mCRC

Presented By

Prof. Nageshwara Arvind Dasari, MD Anderson Cancer Centre, TX, USA

Trial

Phase 3, FRESCO-2

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:21

Second-line avelumab is effective in patients with MSI-H/dMMR mCRC

Presented By

Prof. Julien Taieb, Hopital European George Pompidou, France

Trial

Phase 2, SAMCO-PRODIGE 54

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:13

Trastuzumab-deruxtecan Potential Second-line Therapy Option in HER2-Positive Gastric Cancer

Expert

Dr Elizabeth Smyth; Prof. Eric Van Cutsem

Trial

DESTINY-Gastric01; DESTINY-Gastric02

Conference

ASCO GI 2022

15 November 2022 14:20

Efficacy of Anti-PD-1 Antibodies Plus Multikinase Inhibitors in Advanced Gastric Cancer Patients with or Without Liver Metastases

15 November 2022 13:34

Efficacy of Pembrolizumab Chemotherapy in Gastric Cancer and Tumor Mutational Burden

15 November 2022 13:26